Clinical trial · Interventional
Adherence to Oral Anticancer Treatment Using Electronic Monitoring System
A Pilot Study of Adherence to Oral Anticancer Treatment Using Electronic Monitoring System
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. Moreover, this study is aimed at evaluating the feasibility to use a " Medication Event Monitoring System " (MEMS®) in order to assess adherence of an oral anticancer treatment delivered by dispensary pharmacy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Evaluation of adherence to 3 oral anticancer treatment using a " Medication Event Monitoring System " | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- adherence assessment group
- description
- evaluation of adherence using MEMS
- interventionNames
- Other: Evaluation of adherence to 3 oral anticancer treatment using a " Medication Event Monitoring System "
Primary outcomes (1)
- measure
- evaluation of adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor.
- timeFrame
- everey visit during 6 months
Secondary outcomes (4)
- measure
- evaluation of liberal nurse satisfaction
- timeFrame
- inclusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age \> 18 years * histologically proven malignant tumor * documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor * ambulatory treated subject * Subject who accept to use MEMS monitors to automatically compile their drug dosing histories * Written informed consent Exclusion Criteria: * any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol * patient who does not agreed to participate the program
References
Publications (0)
Data not yet available